The global Hereditary Angioedema market size is projected to reach US$ 2724.1 million by 2026, from US$ 1786.9 million in 2020, at a CAGR of 7.3% during 2021-2026.
The global Hereditary Angioedema market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hereditary Angioedema market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Based on region, the global Hereditary Angioedema market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
The major players that are operating in the global Hereditary Angioedema market are
Pharming Group NV
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Segment by Type
C1 Esterase Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Segment by Application